



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



**Date: 04 February 2025**

<b>To</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001	<b>To</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai – 400051
<b>Security Code: 540596</b>	<b>Symbol: ERIS</b>

**SUBJECT: OUTCOME OF THE BOARD MEETING HELD TODAY, i.e., TUESDAY, FEBRUARY 04, 2025**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Regulation 51 (Part A and Part B of Schedule III) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (“**SEBI Listing Regulations**”) we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., Tuesday, February 04, 2025, inter alia, duly approved and took on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024.

In this regard, the following documents are enclosed:

- A copy of the said financial results along with the limited review report pursuant to Regulation 33 and Regulation 52 of the SEBI Listing Regulations. The limited review reports are submitted with unmodified opinion(s) (free from any qualifications).
- Details as per Regulation 52(4) of SEBI Listing Regulations.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 12:28 P.M.

This is for your information and record.

Thanking You,

**For Eris Lifesciences Limited**

---

**Milind Talegaonkar**  
**Company Secretary & Compliance Officer**  
**Membership No: A26493**

**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ERIS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

*H.S. Sutaria . .*

Hardik Sutaria  
Partner  
Membership No. 116642  
UDIN:25116642BMLMVJ4429

Place: Ahmedabad  
Date: February 04, 2025



Statement of Unaudited Standalone Financial Results For The Quarter And Nine Months Ended December 31, 2024

Particulars	[Rs. in Crore except per share data]					
	For Quarter Ended			For Nine Months ended		For Year Ended
	December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
<b>Revenue from Operations</b>						
Sale of products	390.00	428.75	315.96	1,267.92	1,122.50	1,454.75
Other operating income	9.73	7.81	8.45	25.06	22.91	31.96
<b>Total Revenue from Operations</b>	<b>399.73</b>	<b>436.56</b>	<b>324.41</b>	<b>1,292.98</b>	<b>1,145.41</b>	<b>1,486.71</b>
Other Income	7.79	5.81	3.43	18.76	14.44	34.83
<b>Total Income</b>	<b>407.52</b>	<b>442.37</b>	<b>327.84</b>	<b>1,311.74</b>	<b>1,159.85</b>	<b>1,521.54</b>
<b>Expenses</b>						
Cost of materials consumed	10.93	23.19	23.75	58.52	78.55	96.29
Purchase of stock-in-trade	122.67	112.34	36.24	355.42	159.85	197.02
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(14.52)	(10.20)	4.65	(39.01)	(23.55)	(13.15)
Employee benefits expense	87.04	89.72	80.69	280.51	252.15	331.67
Finance Costs	54.65	56.26	15.14	167.08	28.53	57.42
Depreciation and amortisation expense	46.68	46.16	28.08	138.39	73.25	102.39
Other expenses	94.04	78.88	104.65	271.96	303.98	421.06
<b>Total Expenses</b>	<b>401.49</b>	<b>396.35</b>	<b>293.20</b>	<b>1,232.87</b>	<b>872.76</b>	<b>1,192.70</b>
<b>Profit before Tax</b>	<b>6.03</b>	<b>46.02</b>	<b>34.64</b>	<b>78.87</b>	<b>287.09</b>	<b>328.84</b>
<b>Tax Expense</b>						
Current Tax	-	8.78	5.83	13.47	49.41	57.64
Deferred Tax	4.25	9.14	(2.84)	18.48	(22.53)	(28.52)
<b>Total Tax Expense</b>	<b>4.25</b>	<b>17.92</b>	<b>2.99</b>	<b>31.95</b>	<b>26.88</b>	<b>29.12</b>
<b>Net Profit for the period / year</b>	<b>1.78</b>	<b>28.10</b>	<b>31.65</b>	<b>46.92</b>	<b>260.21</b>	<b>299.72</b>
<b>Other Comprehensive Income/(loss)</b>	<b>(0.42)</b>	<b>(0.11)</b>	<b>(0.15)</b>	<b>(1.25)</b>	<b>(2.10)</b>	<b>(2.76)</b>
Items that will not be reclassified to profit or loss	(0.64)	(0.18)	(0.20)	(1.92)	(3.23)	(4.24)
Income tax relating to items that will not be reclassified to profit or loss	0.22	0.07	0.05	0.67	1.13	1.48
<b>Total Comprehensive Income</b>	<b>1.36</b>	<b>27.99</b>	<b>31.50</b>	<b>45.67</b>	<b>258.11</b>	<b>296.96</b>
Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.61	13.61	13.60	13.61	13.60	13.60
Other Equity						2,510.42
Earnings Per Share (of Rs 1 each) (not annualised) :						
Basic	0.13	2.06	2.33	3.45	19.13	22.04
Diluted	0.13	2.06	2.33	3.44	19.11	22.01

See accompanying notes to the standalone financial results




**Registered & Corporate Office:**

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

1. Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and nine months ended December 31, 2024

Particulars	Numerator	Denominator	Quarter Ended			Nine months ended		Year Ended
			December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	As at March 31, 2024
Debt – Equity Ratio	Total Debt(including lease liabilities)	Total Equity	0.97	1.00	0.35	0.97	0.35	1.02
Debt Service Coverage Ratio	Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans	Finance Costs +Committed Principal repayments made during the period for long term loans	1.37	1.52	1.59	1.47	3.37	3.20
Interest service coverage ratio	Earnings before Interest and Tax	Finance Costs	1.11	1.82	3.29	1.47	11.06	6.73
Outstanding redeemable preference shares (quantity and value)			Nil	Nil	Nil	Nil	Nil	Nil
Capital redemption reserve/debenture redemption reserve (Rs in crore)			0.17	0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)			2,581.40	2,576.86	2,484.42	2,581.40	2,484.42	2,524.02
Net profit after tax (Rs in crore)			1.78	28.10	31.65	46.92	260.21	299.72
Earnings per share:			0.13	2.06	2.33	3.45	19.13	22.04
Current Ratio	Current Assets	Current Liabilities	0.75	0.73	1.85	0.75	1.85	0.83
Long term debt to working capital	Long-term borrowing+Lease liabilities including its current maturity	Current Assets-Current liabilities (excluding current maturity)	(30.59)	(32.79)	1.80	(30.59)	1.80	2.11
Bad debts to Account receivable ratio	Bad debts	Trade receivables	NIL	NIL	NIL	NIL	NIL	NIL
Current liability ratio	Current liabilities	Total liabilities	0.40	0.37	0.34	0.40	0.34	0.80
Total debts to total assets	Total Debt (including lease liabilities)	Total Assets	0.45	0.47	0.24	0.45	0.24	0.48
Debtors' turnover*	Sales	Debtors	6.71	6.55	5.21	6.71	5.21	6.06
Inventory Turnover Ratio*	Cost of goods sold	Average Inventory	3.20	3.19	3.51	3.20	3.51	3.61
Operating margin percent	Earnings before Interest and Tax	Revenue from Operations	15.18%	23.43%	15.35%	19.02%	27.55%	25.98%
Net profit margin percent:	Profit after tax	Revenue from Operations	0.45%	6.44%	9.75%	3.63%	22.72%	20.16%

\*Quarterly Ratios are based on trailing twelve months value



**Notes to financial results**

- 2 The above statement of Standalone Financial Results ("the Statement") of the Company has been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 04, 2025.
- 3 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 4 During the quarter ended December 31, 2024, 23,490 ordinary shares of Rs 1 each were issued and allotted under the Company's Employee Stock Option Scheme 2021 and Company's Employee Stock Option Plan 2017. Consequently, the issued and paid-up Share Capital of the Company as on December 31, 2024 stands increased to Rs 13.61 crore.
- 5 The financial results for the current quarter and nine months ended on December 31, 2024 includes the impact of acquisition of Nephrology And Dermatology business in November 2023 and Indian Branded Formulations business in April 2024 from Biocon Biologicals Limited. The Company is in the process of making final determination of fair values of identified assets and liabilities of Indian branded formulation business acquired in April 2024 for the purpose of Purchase price allocation. Pending this, the business combination has been accounted based on provisional fair valuation report. The results of the current quarter ended December 31, 2024 are not comparable with those of corresponding periods included in the aforesaid statement due to said acquisitions.
- 6 The tax expense of the Company for the current nine months ended December 31, 2024 as a proportion of profit before tax is higher since upto the previous financial year the Company was claiming deduction u/s 80IE of the Income tax Act 1961 in respect of its manufacturing unit in accordance with terms of section 80IE. The previous financial year was the last year to claim the said deduction.
- 7 Pursuant to the Share Subscription Agreement entered into by the Company with Levim Lifetech Private Limited and its shareholders dated January 10, 2025, for acquisition of 30% representing 14,28,660 shares having face value of Rs. 10 per share for consideration amounting to Rs. 51.43 Crores has been agreed. The closure of the transaction is currently in process and is expected to be completed in Q4 of FY 24-25.

For Eris Lifesciences Limited,



Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925

Place: Ahmedabad  
Date: February 04, 2025



## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF ERIS LIFESCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **ERIS LIFESCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
  - (i) Eris Lifesciences Limited (Parent)
  - (ii) Aprica Healthcare Limited (Subsidiary)
  - (iii) Eris Bionxt Private Limited (Subsidiary) (Formerly known as Chemman Labs Private Limited)
  - (iv) Eris Healthcare Private Limited (Subsidiary)
  - (v) Eris M.J. Biopharm Private Limited (Subsidiary)
  - (vi) Eris Pharmaceuticals Limited (Subsidiary) (Formerly known as Eris Pharmaceuticals Private Limited)
  - (vii) Eris Therapeutics Limited (Subsidiary)
  - (viii) Eris Oaknet Healthcare Private Limited (Subsidiary)
  - (ix) Swiss Parenterals Limited (Subsidiary)



**Deloitte  
Haskins & Sells LLP**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of seven subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 357.96 Crore and Rs. 982.88 Crore for the quarter and nine months ended December 31, 2024, total net profit after tax of Rs. 99.35 Crore and Rs. 270.96 Crore for the quarter and nine months ended December 31, 2024, respectively and total comprehensive income of Rs. 99.38 Crore and Rs. 270.87 Crore for the quarter and nine months ended December 31, 2024, respectively, as considered in the Statement. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)

*H. S. Sutaria*

Hardik Sutaria  
Partner  
Membership No. 116642  
UDIN: 25116642BMLMVK5079

Place: Ahmedabad  
Date: February 04, 2025



EY Entrepreneur of the year-2013



FROST & SULLIVAN  
2013 BEST PRACTICES AWARD



Business today/YES bank  
Excellence Awards-2013

**Eris**  
Eris Lifesciences Limited

Statement Of Unaudited Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2024

Particulars	For Quarter Ended			For Nine Months Ended		For Year Ended
	December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
<b>Revenue from Operations</b>						
Sale of products	722.12	738.95	483.48	2,176.66	1,444.03	1,991.30
Other operating income	5.33	2.22	2.82	11.68	14.19	17.85
<b>Total Revenue from Operations</b>	<b>727.45</b>	<b>741.17</b>	<b>486.30</b>	<b>2,188.34</b>	<b>1,458.22</b>	<b>2,009.15</b>
Other Income	4.22	4.55	4.20	10.41	8.67	23.82
<b>Total Income</b>	<b>731.67</b>	<b>745.72</b>	<b>490.50</b>	<b>2,198.75</b>	<b>1,466.89</b>	<b>2,032.97</b>
<b>Expenses</b>						
Cost of materials consumed	69.43	72.16	38.91	208.06	126.64	177.81
Purchase of stock-in-trade	133.22	118.35	50.03	377.14	143.00	201.52
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(25.77)	(4.24)	(0.07)	(41.46)	(7.78)	0.72
Employee benefits expense	125.39	125.63	98.68	383.64	301.34	403.82
Finance Costs	57.17	59.47	18.12	177.01	51.77	84.80
Depreciation and amortisation expense	81.20	80.48	45.72	237.62	128.70	182.61
Other expenses	174.87	164.76	123.24	496.15	368.62	550.45
<b>Total Expenses</b>	<b>615.51</b>	<b>616.61</b>	<b>374.63</b>	<b>1,838.16</b>	<b>1,112.29</b>	<b>1,601.73</b>
<b>Profit before Tax</b>	<b>116.16</b>	<b>129.11</b>	<b>115.87</b>	<b>360.59</b>	<b>354.60</b>	<b>431.24</b>
<b>Tax Expense</b>						
Current Tax	24.86	30.25	19.38	80.45	66.49	82.22
Deferred Tax	4.37	2.51	(4.97)	7.44	(29.32)	(48.03)
<b>Total Tax Expense</b>	<b>29.23</b>	<b>32.76</b>	<b>14.41</b>	<b>87.89</b>	<b>37.17</b>	<b>34.19</b>
<b>Net Profit for the period / year</b>	<b>86.93</b>	<b>96.35</b>	<b>101.46</b>	<b>272.70</b>	<b>317.43</b>	<b>397.05</b>
Attributable to :						
- Owners of the Company	83.63	91.59	102.74	258.39	321.02	391.98
- Non controlling interest	3.30	4.76	(1.28)	14.31	(3.59)	5.07
<b>Other Comprehensive Income</b>	<b>(0.39)</b>	<b>(0.16)</b>	<b>(0.33)</b>	<b>(1.34)</b>	<b>(2.64)</b>	<b>(3.05)</b>
Items that will not be reclassified to profit or loss	(0.57)	(0.25)	(0.41)	(2.01)	(3.85)	(4.61)
Income tax relating to items that will not be reclassified to profit or loss	0.18	0.09	0.08	0.67	1.21	1.56
<b>Total Comprehensive Income</b>	<b>86.54</b>	<b>96.19</b>	<b>101.13</b>	<b>271.36</b>	<b>314.79</b>	<b>394.00</b>
Attributable to :						
- Owners of the Company	83.25	91.43	102.41	257.06	318.38	388.93
- Non controlling interest	3.29	4.76	(1.28)	14.30	(3.59)	5.07
Paid Up Equity Share Capital (Face Value of Rs 1 each)	13.61	13.61	13.60	13.61	13.60	13.60
Other Equity						2,572.52
Earnings Per Share (of Rs 1 each) (not annualised) :						
Basic	6.15	6.73	7.55	18.99	23.60	28.82
Diluted	6.14	6.72	7.54	18.96	23.57	28.79

See accompanying notes to the consolidated financial results



Registered & Corporate Office:


Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054  
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



1. Additional information pursuant to Regulation 52(4) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 as amended for the quarter and Nine Months ended December 31, 2024

Particulars	Numerator	Denominator	Quarter Ended			Nine Months ended		Year Ended
			December 31, 2024 (Unaudited)	September 30, 2024 (Unaudited)	December 31, 2023 (Unaudited)	December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	March 31, 2024 (Audited)
Debt – Equity Ratio	Total Debt(including lease liabilities)	Total Equity	0.79	0.86	0.44	0.79	0.44	0.86
Debt Service Coverage Ratio	Profit after tax-Other income+ Depreciation and amortisation expense+Finance Costs+Committed Principal repayments made during the period for long term loans	Finance Costs +Committed Principal repayments made during the period for long term loans	2.27	2.15	2.28	2.21	3.56	3.56
Interest service coverage ratio	Earnings before Interest and Tax	Finance Costs	3.03	3.17	7.40	3.04	7.85	6.09
Outstanding redeemable preference shares (quantity and value)			NIL	NIL	NIL	NIL	NIL	NIL
Capital redemption reserve/debenture redemption reserve (Rs in crore)			0.17	0.17	0.17	0.17	0.17	0.17
Net worth (Rs in crore)			3,267.09	3,177.15	2,529.54	3,267.09	2,529.54	3,222.03
Net profit after tax (Rs in crore)			86.93	96.35	101.46	272.70	317.43	397.05
Earnings per share:			6.15	6.73	7.55	18.99	23.60	28.82
Current Ratio	Current Assets	Current Liabilities	1.03	1.07	1.85	1.03	1.85	0.91
Long term debt to working capital	Long-term borrowing+Lease liabilities including its current maturity	Current Assets-Current liabilities (excluding current maturity)	6.71	6.05	1.68	6.71	1.68	9.31
Bad debts to Account receivable ratio	Bad debts	Trade receivables	NIL	NIL	NIL	NIL	NIL	NIL
Current liability ratio	Current liabilities	Total liabilities	0.34	0.32	0.30	0.34	0.30	0.66
Total debts to total assets	Total Debt (including lease liabilities)	Total Assets	0.36	0.39	0.26	0.36	0.26	0.39
Debtors' turnover*	Sales	Debtors	5.21	5.09	4.91	5.21	4.91	4.72
Inventory Turnover Ratio*	Cost of goods sold	Average Inventory	2.90	2.90	2.61	2.90	2.61	2.37
Operating margin percent	Earnings before Interest and Tax	Revenue from Operations	23.83%	25.44%	27.55%	24.57%	27.87%	25.68%
Net profit margin percent:	Profit after tax	Revenue from Operations	11.95%	13.00%	20.86%	12.46%	21.77%	19.76%

\*Quarterly Ratios based on Trailing Twelve months values



## Notes to financial results

- 2 The above statement of Consolidated Financial Results ("the Statement") of the Company has been recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 04, 2025.
- 3 The Company is primarily engaged in one business segment namely - "Pharmaceuticals" - as determined by the chief operating decision maker in accordance with Ind AS 108 - "Operating Segment".
- 4 During the quarter ended December 31, 2024, 23,490 ordinary shares of Rs 1 each were issued and allotted under the Company's Employee Stock Option Scheme 2021 and Company's Employee Stock Option Plan 2017. Consequently, the issued and paid-up Share Capital of the Company as on December 31, 2024 stands increased to Rs 13.61 crore.
- 5 The financial results for the current quarter and nine months ended on December 31, 2024 includes the impact of acquisition of Swiss Parenterals Limited in February 2024, Nephrology and Dermatology business in November 2023 from Biocon Biologicals Limited and Indian Branded Formulations business in April 2024 from Biocon Biologicals Limited. The Parent Company is in the process of making final determination of fair values of identified assets and liabilities of Swiss Parenterals Limited acquired in February 2024 and Indian branded formulation business acquired in April 2024 for the purpose of Purchase price allocation. Pending this, the business combination has been accounted based on provisional fair valuation report. The results of the current quarter ended December 31, 2024 are not comparable with those of corresponding periods included in the aforesaid statement due to said acquisitions.
- 6 During the previous quarter, the Company acquired 1,43,13,418 equity shares representing 100% of the equity share capital of Eris Bionxt Private Limited (formerly known as Chemman Labs Private Limited) from its erstwhile shareholders for a consideration of Rs. 27 Crores. The transaction achieved closure in October 2024, on completion of all relevant conditions precedent to the transaction. The Parent Company is in the process of making final determination of fair values of identified assets and liabilities for the purpose of Purchase price allocation. Pending this, the business combination has been accounted based on provisional fair valuation report. The results of the current quarter ended December 31, 2024 are not comparable with those of corresponding periods included in the aforesaid statement due to said acquisition.
- 7 Pursuant to the Share Subscription Agreement entered into by the Parent Company with Levim Lifetech Private Limited and its shareholders dated January 10, 2025, for acquisition of 30% representing 14,28,660 shares having face value of Rs. 10 per share for consideration amounting to Rs. 51.43 Crores has been agreed. The closure of the transaction is currently in process and is expected to be completed in Q4 of FY 24-25.

For Eris Lifesciences Limited,



Amit Bakshi  
Chairman and Managing Director  
DIN : 01250925

Place: Ahmedabad  
Date: February 04, 2025

